At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Single-Center, Randomized, 3-Period Crossover Study in Healthy Volunteers to Evaluate the Absorption of WTX101 After Single Dose Administration of an Enteric Coated Formulation With and Without Food and a Non-Coated Formulation Coadministered With a Proton Pump Inhibitor Without Food
In Brief
A Phase 1 clinical trial evaluating ALXN1840 Enteric-coated Tablet, ALXN1840 Non-coated Capsule, and 1 other intervention for Healthy. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This was single-center, open-label, randomized, 3-period, 3-treatment, 6-sequence crossover study evaluating the PK of single doses of WTX101 in healthy participants based on the measurement of plasma total Mo concentration.
Study Details
Timeline
Interventions
ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.
ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.